Abstract
In order to evaluate the effectiveness of CMX nebulizer therapy in chronic paranasal sinusitis, the CMX concentration in the maxillary sinus and in the nasal cavity after CMX nebulization was measured in chronic paranasal sinusitis patients.
Following the inhalation of 2ml of 1% CMX solutuion (20mg potency) using a supersonic wave nebulizer, the mean CMX concentration in the mucous membrane surface of the maxillary sinus reached 6.11μg/ml-26.41μg/ml. This was higher than the MIC needed against the causative organisms of paranasal sinusitis.
CMX nebulizer therapy is expected to exert a direct effect on the paranasal sinus, and seems to be extremely useful in the treatment of paranasal sinusitis.
